Srinivas Chatla

Dr. Srinivas Chatla

Fels Cancer Institute for Personalized Medicine, Temple University, Philadelphia, Pennsylvania, USA
orcid
Associate Scientist

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AKAhmed Kamal
Ahmed Kamal
KRK. Srinivasa Reddy
K. Srinivasa Reddy
MKM. Naseer A. Khan
M. Naseer A. Khan
RSRajesh V.C.R.N.C. Shetti
Rajesh V.C.R.N.C. Shetti
MRM. Janaki Ramaiah
M. Janaki Ramaiah
MBMadan Barkume
Madan Barkume

15 November 2018 in Oncogene
Verified
Journal Article
Open access
PDF file
SKSushil Kumar
Sushil Kumar
RSRatnesh Kumar Srivastav
Ratnesh Kumar Srivastav
DWDavid W. Wilkes
David W. Wilkes
TRTaylor Ross
Taylor Ross
SKSabrina Kim
Sabrina Kim
RCRumela Chakrabarti
Rumela Chakrabarti
Aberrant Notch signaling is implicated in several cancers, including breast cancer. However, the mechanistic details of the specific receptors and function of ligand-mediated Notch signaling that promote breast cancer remains elusive. In our studies we show that DLL1, a Notch signaling ligand, is significantly overexpressed in ERα+ luminal breast cancer. Intriguingly, DLL1 overexpression correlates with poor prognosis in ERα+ luminal breast cancer, but not in other subtypes of breast cancer. In addition, this effect is specific to DLL1, as other Notch ligands (DLL3, JAGGED1, and JAGGED2) do not influence the clinical outcome of ERα+ patients. Genetic studies show that DLL1-mediated Notch signaling in breast cancer is important for tumor cell proliferation, angiogenesis, and cancer stem cell function. Consistent with prognostic clinical data, we found the tumor-promoting function of DLL1 is exclusive to ERα+ luminal breast cancer, as loss of DLL1 inhibits both tumor growth and lung metastasis of luminal breast cancer. Importantly, we find that estrogen signaling stabilizes DLL1 protein by preventing its proteasomal and lysososmal degradations. Moreover, estrogen inhibits ubiquitination of DLL1. Together, our results highlight an unexpected and novel subtype-specific function of DLL1 in promoting luminal breast cancer that is regulated by estrogen signaling. Our studies also emphasize the critical role of assessing subtype-specific mechanisms driving tumor growth and metastasis to generate effective subtype-specific therapeutics.

10 September 2010 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
AKAhmed Kamal
Ahmed Kamal
DDD. Dastagiri
D. Dastagiri
MRM. Janaki Ramaiah
M. Janaki Ramaiah
JRJ. Surendranadha Reddy
J. Surendranadha Reddy
EBE. Vijaya Bharathi
E. Vijaya Bharathi
MPManika Pal‐Bhadra
Manika Pal‐Bhadra

1 January 2012 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SCSrivari Chandrasekhar
Srivari Chandrasekhar
SPSreerangam N.C.V.L. Pushpavalli
Sreerangam N.C.V.L. Pushpavalli
Srinivas ChatlaSrinivas Chatla
Srinivas Chatla
DMDebasmita Mukhopadhyay
Debasmita Mukhopadhyay
BGBogonda Ganganna
Bogonda Ganganna
UBUtpal Bhadra
Utpal Bhadra

15 November 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZLZhiyan Silvia Liu
Zhiyan Silvia Liu
SSSayantani Sinha
Sayantani Sinha
MBMaxwell Bannister
Maxwell Bannister
ASAxia Song
Axia Song
EAErica Arriaga-Gomez
Erica Arriaga-Gomez
HNHai Dang Nguyen
Hai Dang Nguyen
RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop–associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription–replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer. Significance: Spliceosome-mutant leukemias accumulate R-loops and require PARP1 to resolve transcription–replication conflicts and genomic instability, providing rationale to repurpose FDA-approved PARP inhibitors for patients carrying spliceosome gene mutations.

2 November 2023 in Blood
Verified
Journal Article
Open access
PDF file
LWLimei Wu
Limei Wu
QLQiqi Lin
Qiqi Lin
Srinivas ChatlaSrinivas Chatla
Srinivas Chatla
SASurya Prakash Amarachintha
Surya Prakash Amarachintha
AWAndrew F. Wilson
Andrew F. Wilson
Wei DuWei Du
Wei Du
The cross talk between extrinsic niche-derived and intrinsic hematopoietic stem cell (HSC) factors controlling HSC maintenance remains elusive. Here, we demonstrated that amphiregulin (AREG) from bone marrow (BM) leptin receptor (LepR+) niche cells is an important factor that mediates the cross talk between the BM niche and HSCs in stem cell maintenance. Mice deficient of the DNA repair gene Brca2, specifically in LepR+ cells (LepR-Cre;Brca2fl/fl), exhibited increased frequencies of total and myeloid-biased HSCs. Furthermore, HSCs from LepR-Cre;Brca2fl/fl mice showed compromised repopulation, increased expansion of donor-derived, myeloid-biased HSCs, and increased myeloid output. Brca2-deficient BM LepR+ cells exhibited persistent DNA damage–inducible overproduction of AREG. Ex vivo treatment of wild-type HSCs or systemic treatment of C57BL/6 mice with recombinant AREG impaired repopulation, leading to HSC exhaustion. Conversely, inhibition of AREG by an anti–AREG-neutralizing antibody or deletion of the Areg gene in LepR-Cre;Brca2fl/fl mice rescued HSC defects caused by AREG. Mechanistically, AREG activated the phosphoinositide 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, promoted HSC cycling, and compromised HSC quiescence. Finally, we demonstrated that BM LepR+ niche cells from other DNA repair–deficient and aged mice also showed persistent DNA damage–associated overexpression of AREG, which exerts similar negative effects on HSC maintenance. Therefore, we identified an important factor that regulates HSCs function under conditions of DNA repair deficiency and aging.